Primaquine

Pharmacologic Category

Aminoquinoline (Antimalarial); Antimalarial Agent

Dosing: Adult

Note: Screen for G6PD deficiency prior to initiating treatment. Dosage expressed as mg of base (15 mg base = 26.3 mg primaquine phosphate).

Malaria: Oral:

Treatment or prevention of relapse of P. vivax malaria: 15 mg once daily in combination with chloroquine for 14 days (maximum dose: 15 mg/day)

Treatment of uncomplicated P. vivax and P. ovale malaria (off-label use): 30 mg once daily for 14 days with chloroquine or hydroxychloroquine; alternative regimen (for mild G6PD deficiency or as an alternative to daily regimen): 45 mg once weekly for 8 weeks (use only after consultation with an infectious disease/tropical medicine expert) (CDC 2013)

Chemoprophylaxis (off-label use): 30 mg once daily; start 1 to 2 days prior to travel and continue for 7 days after departure from malaria-endemic area (CDC Yellow Book 2014)

Presumptive antirelapse therapy for P. vivax and P. ovale malaria (off-label use): 30 mg once daily for 14 days after departure from malaria-endemic area (CDC Yellow Book 2014)

Pneumocystis pneumonia (PCP) treatment in HIV-infected patients (alternative to preferred therapy) (off-label use): Oral: 30 mg once daily for 21 days (in combination with clindamycin) (HHS [OI adult 2015])

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Pediatric

Note: Dosage expressed as mg of base (15 mg base = 26.3 mg primaquine phosphate):

Malaria: Oral:

Treatment or relapse prevention of P. vivax malaria: Infants, Children, and Adolescents: 0.5 mg base/kg once daily for 14 days; maximum single dose: 30 mg base (CDC, 2013)

Treatment of uncomplicated malaria (P. vivax and P. ovale): Infants, Children, and Adolescents: 0.5 mg base/kg once daily for 14 days with chloroquine or hydroxychloroquine; maximum single dose: 30 mg base (CDC, 2013)

Prevention of malaria (primarily P. vivax):

Non-HIV-exposed/-positive: Infants, Children and Adolescents: 0.5 mg base/kg once daily; maximum single dose: 30 mg base; initiate 1 to 2 days prior to travel and continue once daily while in the area with malaria risk, and for 7 days after departure from malaria-endemic area (CDC, 2014)

HIV-exposed/-positive:

Primary prophylaxis: Infants and Children: 0.6 mg base/kg once daily; maximum single dose: 30 mg base; initiate 1 day prior to travel and continue once daily while in the area with malaria risk, and for 3 to 7 days after departure from malaria-endemic area (DHHS [pediatric], 2013)

Secondary prophylaxis and antirelapse therapy: Infants, Children, and Adolescents: 0.5 mg base/kg once daily for 14 days after departure from malaria-endemic area; maximum single dose: 30 mg base (CDC, 2014)

Pneumocystis jirovecii pneumonia (PCP) (HIV-exposed/-positive) treatment: Oral:

Infants and Children: 0.3 mg base/kg once daily for 21 days in combination with clindamycin; maximum single dose: 30 mg base (DHHS [pediatric], 2013)

Adolescents: 30 mg base once daily for 21 days in combination with clindamycin (DHHS [adult], 2013)

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Use: Labeled Indications

Malaria: Radical cure (prevention of relapse) of vivax malaria

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Malaria chemoprophylaxisLevel of Evidence [G]

Based on the Centers for Disease Control and Prevention Health Information for National Travel, primaquine is effective and recommended for prophylaxis of malaria when the travel is of short-duration to areas with principally Plasmodium vivax malaria and last-minute travelers. Must rule out G6PD deficiency prior to use.

Pneumocystis pneumonia (PCP) in HIV-infected patientsLevel of Evidence [G]

Based on the US Department of Health and Human Services (HHS) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, primaquine in combination with clindamycin is an effective and recommended alternative agent in the treatment of Pneumocystis pneumonia (PCP) in HIV-infected patients.

Presumptive antirelapse therapy for Plasmodium vivax and Plasmodium ovale malariaLevel of Evidence [G]

Based on the Centers for Disease Control and Prevention Health Information for National Travel, primaquine is effective and recommended for presumptive antirelapse therapy (terminal prophylaxis) to decrease the risk for relapses of P. vivax and Plasmodium ovale malaria. Must rule out G6PD deficiency prior to use.

Uncomplicated Plasmodium vivax and Plasmodium ovale malariaLevel of Evidence [G]

Based on the Centers for Disease Control and Prevention guidelines for treatment of malaria, primaquine is effective and recommended for the treatment of uncomplicated Plasmodium vivax or Plasmodium ovale malaria. Must rule out G6PD deficiency prior to use.

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

Malaria:

CDC, “Guidelines for Treatment of Malaria in the United States,” Table - July 2013

CDC, “Health Information for National Travel, 2016 ” (The Yellow Book)

CDC, “Treatment of Malaria (Guidelines for Clinicians),” July 2013

WHO, “Guidelines for the Treatment of Malaria,” 2015

Opportunistic Infections:

HHS, Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children, November 2013

HHS, Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, September 2015

Administration: Oral

Administer with meals to decrease adverse GI effects. If patient vomits within 30 minutes of taking a dose, then they should repeat the dose (CDC 2013).

Administration: Pediatric

Oral: Administer with meals to decrease adverse GI effects; drug has a bitter taste

Storage/Stability

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.

Extemporaneously Prepared

A 6 mg base/5 mL oral suspension may be made using tablets. Crush ten 15 mg base tablets and reduce to a fine powder. In small amounts, add a total of 10 mL Carboxymethylcellulose 1.5% and mix to a uniform paste; mix while adding Simple Syrup, NF to almost 125 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 125 mL. Label "shake well" and "refrigerate". Stable 7 days.

Nahata MC, Pai VB, and Hipple TF, Pediatric Drug Formulations, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat or prevent malaria.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Abdominal cramps

• Abdominal pain

• Vomiting

• Nausea

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Methemoglobinemia like blue or gray color of the lips, nails, or skin; arrhythmia; seizures; severe dizziness or passing out; severe headache; fatigue; loss of strength and energy; or shortness of breath

• Dark urine

• Chills

• Yellow skin

• Dizziness

• Fast heartbeat

• Abnormal heartbeat

• Severe loss of strength and energy

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Contraindications

Severe G6PD deficiency; pregnancy; use in acutely ill patients who have a tendency to develop granulocytopenia (eg, rheumatoid arthritis, systemic lupus erythematosus); concurrent use with other medications causing hemolytic anemia or myeloid bone marrow suppression; concurrent use with or recent use of quinacrine

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to primaquine or any component of the formulation

Documentation of allergenic cross-reactivity for aminoquinolines is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concerns related to adverse effects:

• Cardiovascular effects: May cause QT prolongation; monitor ECG in patients with cardiac disease, long QT syndrome, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (<50 beats per minute), and during concomitant administration with QT interval prolonging agents.

• Hematologic effects: Anemia, methemoglobinemia, and leukopenia have been associated with primaquine use; monitor during treatment; do not exceed recommended dosage and duration. Closely monitor patients who have a family or personal history of hemolytic anemia or who have had a prior hematologic adverse reaction attributed to primaquine. Immediately discontinue if marked darkening of the urine or sudden decrease in hemoglobin concentration or leukocyte count occurs.

• Hemolytic anemia: Promptly discontinue with signs of hemolytic anemia (darkening of urine, marked fall in hemoglobin or erythrocyte count). Moderate to severe hemolytic reactions may occur in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and personal or familial history of favism. Geographic regions with a high prevalence of G6PD deficiency (eg, Africa, southern Europe, Mediterranean region, Middle East, southeast Asia, Oceania) are associated with a higher incidence of hemolytic anemia.

Disease-related concerns:

• G6PD deficiency: Screen for G6PD deficiency prior to therapy initiation. Use is contraindicated in patients with severe G6PD deficiency. Assess benefits/risks of treatment when considering use in patients with mild to moderate G6PD deficiency or those patients whose G6PD status is unknown and testing is not available. Also assess risk factors for G6PD deficiency or favism in patients with unknown G6PD status. If a decision is made to administer primaquine to a patient with mild to moderate G6PD deficiency or unknown G6PD status (when testing is not available), perform baseline hematocrit and hemoglobin testing and closely monitor hematological parameters (eg, at day 3 and 8). Immediately discontinue treatment if signs of hemolytic anemia occur.

• NADH methemoglobin reductase deficiency: Use with caution in patients with a personal or family history of NADH methemoglobin reductase deficiency; methemoglobinemia may occur.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Dosage form specific issues:

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.

* See Cautions in AHFS Essentials for additional information.

Pregnancy Considerations

Primaquine is contraindicated in pregnant women.

Malaria infection in pregnant women may be more severe than in nonpregnant women and has a high risk of maternal and perinatal morbidity and mortality. Therefore, pregnant women and women who are likely to become pregnant are advised to avoid travel to malaria-risk areas. When treatment is needed, other agents are preferred (CDC Yellow Book 2016). Consult current CDC guidelines for the treatment of malaria during pregnancy.

Sexually active females should have a pregnancy test prior to treatment with primaquine. Females of reproductive potential should use effective contraception during therapy and until the next menses following discontinuation of treatment. Males with female partners of reproductive potential should use condoms during therapy and for 3 months after treatment is discontinued.

Breast-Feeding Considerations

Primaquine and carboxyprimaquine are present in breast milk.

The relative infant dose (RID) of primaquine is <2% as calculated by the authors of a study and compared to a weight-adjusted infant dose of 0.5 mg/kg/day (Gilder 2018).

In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).

The RID was calculated following administration of oral primaquine 0.5 mg/kg/day for 14 days to 21 breastfeeding women for the radical cure of P. vivax malaria. All mothers and their children were G6PD-normal and all infants were at least 28 days of age prior to the study. Maximum breast milk concentrations were 26.8 to 116 ng/mL for primaquine and 3.98 ng/mL to 28.4 ng/mL for carboxyprimaquine. Total daily infant doses via breast milk ranged from 1.06 mcg/kg/day to 9.10 mcg/kg/day and the RID ranged from 0.212% to 1.82%. Primaquine was measurable in the capillary plasma of one infant at one time point during the study; primaquine and carboxyprimaquine concentrations were below the limits of quantification in all other infant plasma samples obtained. Adverse events were not observed in the breastfed infants (Gilder 2018).

Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. If therapy is needed, the mother and infant should be tested for G6PD deficiency; primaquine may be used in breastfeeding mothers and infants with normal G6PD levels and concentrations (CDC Yellow Book 2016). The World Health Organization also considers primaquine to be compatible with breastfeeding in G6PD-normal infants; infants should be monitored for hemolysis and jaundice, especially if premature or <1 month of age (WHO 2002).

Briggs' Drugs in Pregnancy & Lactation

• Primaquine

Adverse Reactions

Frequency not defined.

Cardiovascular: Cardiac arrhythmia, dizziness, prolonged Q-T interval on ECG

Dermatologic: Pruritus, skin rash

Gastrointestinal: Abdominal cramps, epigastric distress, nausea, vomiting

Hematologic & oncologic: Anemia, hemolytic anemia (in patients with G6PD deficiency), leukopenia, methemoglobinemia (in NADH-methemoglobin reductase-deficient individuals)

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• QuiNIDine/QuiNINE Derivative Allergy

Metabolism/Transport Effects

Substrate of CYP2D6 (major), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions Open Interactions

Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible. When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity. Risk D: Consider therapy modification

Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). Risk C: Monitor therapy

Artemether: May enhance the QTc-prolonging effect of Primaquine. Artemether may increase the serum concentration of Primaquine. Risk C: Monitor therapy

Artesunate: May enhance the QTc-prolonging effect of Primaquine. Artesunate may increase the serum concentration of Primaquine. Risk C: Monitor therapy

Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk D: Consider therapy modification

Beta-Blockers: Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers. Exceptions: Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol; Sotalol. Risk C: Monitor therapy

Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Cardiac Glycosides: Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides. Risk C: Monitor therapy

Chloroquine: May increase the serum concentration of Primaquine. Risk C: Monitor therapy

CloBAZam: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Primaquine. Management: Monitor for signs and symptoms of possible treatment failure with primaquine in patients who are taking strong CYP2D6 inhibitors. If efficacy of primaquine is compromised, may consider adjusting therapies. Risk D: Consider therapy modification

CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling. Risk D: Consider therapy modification

Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Risk D: Consider therapy modification

Dacomitinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of dacomitinib with CYP2D6 subtrates that have a narrow therapeutic index. Risk D: Consider therapy modification

Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions. Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M. Risk D: Consider therapy modification

Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased. Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects. Risk D: Consider therapy modification

Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring. Risk D: Consider therapy modification

Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy

Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option. Risk X: Avoid combination

Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial). Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible. Risk X: Avoid combination

Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane. Risk D: Consider therapy modification

Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Gene Testing Recommended

• G6PD - Primaquine

Genes of Interest

• Cytochrome P450 3A4

Monitoring Parameters

Periodic CBC (in G6PD normal patients), visual color check of urine, glucose, electrolytes; if hemolysis suspected, monitor CBC, haptoglobin, peripheral smear, urinalysis dipstick for occult blood, G6PD deficiency screening (prior to initiating treatment); baseline hematocrit and hemoglobin testing and periodic CBC (eg, at day 3 and 8) in patients with mild to moderate G6PD deficiency or unknown G6PD status (when testing is not available); ECG (in patients at risk for QT prolongation). Pregnancy test prior to therapy in sexually active females.

Advanced Practitioners Physical Assessment/Monitoring

Screen for G6PD deficiency prior to beginning therapy. Obtain periodic CBC, visual color check of urine, glucose, and electrolytes. If hemolysis is suspected, obtain CBC, haptoglobin, peripheral smear, and urinalysis dipstick for occult blood. Obtain baseline hematocrit/hemoglobin and periodic CBC in patient with mild to moderate G6PD deficiency. Obtain ECG in patients at risk for QT prolongation. Assess other medicines patient may be taking, alternate therapy or dosage adjustments may be needed. Assess for signs of hemolytic anemia or other hematologic effects.

Nursing Physical Assessment/Monitoring

Check ordered labs and report any abnormalities. Monitor for signs and symptoms of hemolytic anemia (dark urine, fall in hemoglobin or erythrocyte count) or infection; instruct patient to report.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral, as phosphate:

Generic: 26.3 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral, as phosphate:

Generic: 26.3 mg

Anatomic Therapeutic Chemical (ATC) Classification

• P01B03

Generic Available (US)

Yes

Pricing: US

Tablets (Primaquine Phosphate Oral)

26.3 mg (per each): $1.80 - $2.13

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Primaquine is an antiprotozoal agent active against exoerythrocytic stages of Plasmodium ovale and P. vivax, also active against the primary exoerythrocytic stages of P. falciparum and gametocytes of Plasmodia; disrupts mitochondria and binds to DNA

Pharmacodynamics/Kinetics

Absorption: Well absorbed

Metabolism: Hepatic to carboxyprimaquine (active) via CYP1A2

Half-life elimination: 7 hours; reported range: 3.7 to 9.6 hours

Time to peak, serum: 1 to 3 hours

Excretion: Urine (small amounts as unchanged drug)

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions.

Related Information

• Drugs With Actionable Pharmacogenomic Recommendations
• Relative Infant Dose

Index Terms

Primaquine Phosphate; Prymaccone

FDA Approval Date

January 23, 1952

References

Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.[PubMed 3960626]

Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi: 10.1002/cpt.377.[PubMed 27060684]

Centers for Disease Control and Prevention (CDC). CDC Health Information for International Travel. New York: Oxford University Press; 2014; Chapter 3. Available at http://wwwnc.cdc.gov/travel/page/yellowbook-home-2014

Centers for Disease Control and Prevention. CDC Health Information for International Travel 2016. New York, NY: Oxford University Press; 2016. http://wwwnc.cdc.gov/travel/page/yellowbook-home-2014.

Centers for Disease Control and Prevention (CDC), “Guidelines for Treatment of Malaria in the United States.” 2013. Available at http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf

Centers for Disease Control and Prevention, “Pneumocystis jiroveci (formerly carinii) Pneumonia (PCP).” Available at http://dpd.cdc.gov/dpdx/HTML/Pneumocystis.htm. Accessed May 15, 2013.

Centers for Disease Control and Prevention (CDC), “Treatment of Malaria (Guidelines for Clinicians).” 2013. Available at http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf

Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm.[PubMed 6423951]

DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf.

DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA)," May 7, 2013. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf

Gilder ME, Hanpithakphong W, Hoglund RM, et al. Primaquine pharmacokinetics in lactating women and breastfed infant exposures. Clin Infect Dis. 2018;67(7):1000-1007. doi: 10.1093/cid/ciy235.[PubMed 29590311]

HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed October 8, 2015

Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.[PubMed 12534540]

Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. doi: 10.1056/NEJM200007133430208.[PubMed 10891521]

Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.[PubMed 10985636]

Lynk A and Gold R, “Review of 40 Children With Imported Malaria,” Pediatr Infect Dis J, 1989, 8(11):745-50.[PubMed 2594448]

Panisko DM and Keystone JS, “Treatment of Malaria - 1990,” Drugs, 1990, 39(2):160-89.[PubMed 2183998]

Primaquine phosphate [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; June 2017.

Primaquine [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc; March 2017.

Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.[PubMed 7746084]

White NJ, “The Treatment of Malaria,” N Engl J Med, 1996, 335(11):800-6.[PubMed 8703186]

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/.

Wyler DJ, “Malaria Chemoprophylaxis for the Traveler,” N Engl J Med, 1993, 329(1):31-7.[PubMed 8505942]

Brand Names: International

Jasoprim (BD); Kanoprim (BD); Malafree (KR); Malirid (IN); PMQ-INGA (IN); Pquin (BD); Primacin (AU); Remaquin (BD)

Last Updated 2/20/20